Amicus Therapeutics (NASDAQ:FOLD) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a strong-buy rating in a research report released on Saturday morning.

Several other equities research analysts have also recently weighed in on FOLD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Amicus Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Thursday, September 18th. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.57.

Amicus Therapeutics Trading Down 0.3%

FOLD traded down $0.03 on Friday, hitting $8.87. 3,896,095 shares of the company were exchanged, compared to its average volume of 4,189,166. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $11.36. The firm has a fifty day simple moving average of $8.30 and a two-hundred day simple moving average of $7.09. The stock has a market capitalization of $2.74 billion, a PE ratio of -73.91 and a beta of 0.66.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The business had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The firm’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts expect that Amicus Therapeutics will post 0.15 earnings per share for the current year.

Insiders Place Their Bets

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of the stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total value of $243,864.93. Following the completion of the sale, the insider owned 322,618 shares in the company, valued at approximately $3,068,097.18. This represents a 7.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. raised its stake in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the period. Strs Ohio purchased a new stake in Amicus Therapeutics during the 1st quarter valued at approximately $30,000. Versant Capital Management Inc grew its holdings in Amicus Therapeutics by 499.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,387 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 3,497 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.